Conference Proceedings

Donor T Cells Maintain Myeloma-Immune Equilibrium after Autologous Stem Cell Transplantation and Concurrent Immunotherapy Promotes Cure

Simone A Minnie, David Smith, Kate H Gartlan, Thomas S Watkins, Kate A Markey, Camille Guillerey, Rachel D Kuns, Kelly R Locke, Antiopi Varelias, Ping Zhang, Nicholas Huntington, Marta Chesi, John J Miles, Mark J Smyth, Slavica Vuckovic, Geoffrey R Hill

Blood | AMER SOC HEMATOLOGY | Published : 2018


Abstract Autologous stem cell transplantation (ASCT) remains an important consolidation treatment for multiple myeloma (MM) patients, even in the era of novel agents. The prolongation of plateau-phase induced by ASCT is generally attributed to intensive cytoreduction. However, ASCT generates inflammation and profound lymphodepletion, which may result in hitherto unexpected immunological effects. To investigate potential immunological contributions to myeloma control after ASCT, we developed preclinical models of transplantation for MM using Vk*MYC myeloma that generates bony lytic lesions, a serum M band and marrow plasmacytosis that are hallmarks of clinical disease. ..

View full abstract